Helsinn initiates two new global Phase III studies with anamorelin
March 07, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn initiates two new global Phase III studies with anamorelin Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung...